Get the latest news, insights, and market updates on MRNA (Moderna, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
3 Stocks Under $50 with Warning Signs
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market. Feb 18, 2026 - $MRNA
These Stocks Are Today’s Movers: Nvidia, Palantir, Garmin, Global Payments, Palo Alto, Moderna, Caesars, and More
Stocks rose Wednesday after the latest policy meeting minutes showed Federal Reserve officials chose to leave the federal-funds rate unchanged at their January meeting. Facebook owner Meta Platforms is expanding its business with the chip designer in a deal likely to be worth tens of billions of dollars. Meta will use millions of Nvidia’s Blackwell and Rubin graphics processing units, a reminder that Nvidia is still the leading player in artificial-intelligence processors. Feb 18, 2026 - $MRNA
Stocks to Watch Wednesday: Sandisk, Moderna, Caesars, Kenvue
↗️ Moderna (MRNA): The FDA agreed to review Moderna’s seasonal flu shot after the vaccine maker said it would run extra tests in the elderly. Shares jumped nearly 5% following the U-turn. ↗️ Analog Devices (ADI): The chip maker posted better-than-forecast quarterly results and guidance. Feb 18, 2026 - $MRNA
Podcast: Stocks Rise on Chips Momentum
Stocks ended the day ahead, powered by a megadeal between Nvidia and Meta Platforms, and better-than-forecast results from Analog Devices. Plus, Moderna shares jumped after FDA's about-face on reviewing the flu vaccine. Feb 18, 2026 - $MRNA
FDA Reverses Course and Will Now Review Moderna’s Flu Shot
The Food and Drug Administration reversed course and agreed to begin a review of Moderna’s application to sell a new seasonal flu shot after the vaccine maker agreed to conduct additional testing in the elderly. The move means that Moderna’s experimental flu shot is largely back on track after the FDA’s surprise decision earlier this month to refuse to start a review of its application. The decision came after discussions with White House and health department officials, people familiar with the matter said. Feb 18, 2026 - $MRNA
FDA Flu Setback Tests Moderna’s mRNA Pipeline And Regulatory Assumptions
FDA issues a surprise refusal to review Moderna's mRNA-based flu vaccine filing, despite earlier agreement on trial design. Decision is described as unprecedented, with no cited safety or efficacy concerns in the application. The vaccine is under review in Europe, Canada, and Australia, while the US process stalls. Moderna, listed as NasdaqGS:MRNA, is best known for its mRNA based Covid 19 vaccine and has been working to extend that platform into seasonal flu and other respiratory diseases... Feb 16, 2026 - $MRNA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple